MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • MDS Virtual Congress 2020

    A Discrete-Choice Experiment Evaluating Preferences for On-Demand Treatments for Patients with Parkinson’s Disease and “OFF” Episodes

    A. Thach, J. Sutphin, J. Coulter, C. Mansfield (Marlborough, MA, USA)

    Objective: To quantify patient preferences for on-demand treatments among patients with Parkinson’s disease (PD) and “OFF” episodes. Background: Patients with PD develop potentially disabling “OFF”…
  • MDS Virtual Congress 2020

    Budget Impact of Apomorphine Sublingual Film for On-Demand Treatment of Patients With Parkinson’s Disease and “OFF” Episodes

    A. Thach, N. Kirson, M. Zichlin, I. Dieye, E. Pappert, G. Williams (Marlborough, MA, USA)

    Objective: To estimate the budget impact of introducing apomorphine sublingual film (APL-130277; APL) as an on-demand treatment for patients with Parkinson’s disease (PD) and “OFF”…
  • MDS Virtual Congress 2020

    On-Demand Treatment Preferences of Patients with Parkinson’s Disease and “OFF” Episodes: Heterogeneity Across Patient Subgroups

    A. Thach, J. Coulter, C. Leach, J. Sutphin, C. Mansfield (Marlborough, MA, USA)

    Objective: To quantify preference heterogeneity for on-demand treatments among patients with Parkinson’s disease (PD) and “OFF” episodes. Background: Patients with PD commonly experience “OFF” episodes.…
  • MDS Virtual Congress 2020

    Randomized, placebo-controlled study investigating the safety, pharmacokinetics and efficacy of inhaled apomorphine in Parkinson’s disease patients

    E. Thijssen, J. den Heijer, D. Puibert, M. Lei, D. Hasegawa, K. Keum, K. Mochel, P. Roset, E. van Brummelen, T. Naranda, G. Groeneveld (Leiden, Netherlands)

    Objective: To evaluate the safety, pharmacokinetics (PK) and efficacy of single-dose apomorphine inhalation in PD patients. Background: Apomorphine is a dopamine agonist, approved for treating…
  • MDS Virtual Congress 2020

    Passive monitored daily motor behavior significantly relates to quality of life in early Parkinson’s disease

    A. Thomann, K. Taylor, F. Lipsmeier, E. Volkova-Volkmar, R. Postuma, W.Y Cheng, B. van Lier, D. Trundell, W. Zago, A. Boulay, G. Pagano, C. Gossens, M. Lindemann (Basel, Switzerland)

    Objective: To investigate whether passively acquired measures of gait and hand gestures are associated with health-related quality of life (HrQoL; PDQ-39) and health-state (EQ-5D-5L) in…
  • MDS Virtual Congress 2020

    The Cognitive Training In Parkinson Study (COGTIPS), a randomized controlled trial

    T. van Balkom, H. Berendse, Y. v.d. Werf, J. Twisk, R. Hagen, T. Berk, O. v.d. Heuvel, C. Vriend (Amsterdam, Netherlands)

    Objective: In this randomized controlled trial [1], our objective was to assess the effect of online home-based cognitive training on objective cognitive functioning and subjective…
  • MDS Virtual Congress 2020

    Prevalence and Characteristics of Postural Deformities in Thai Patients with Parkinson’s Disease

    T. Wangthumrong, C. Pongmala, Y. Pitakpatapee, J. Srikajon, M. Vichutavate, P. Srivanitchpoom (Bangkok, Thailand)

    Objective: We aimed to investigate the prevalence, clinical characteristics and quality of life (QoL) in Thai Parkinson's disease (PD) patients with postural deformities (PostD) and…
  • MDS Virtual Congress 2020

    A pooled analysis of four pivotal, randomized controlled trials of istradefylline, an adenosine A2A receptor antagonist: Efficacy as adjunct to levodopa in Parkinson’s disease (PD)

    C. Waters, R. Hauser, K. Toyama, J. Parno, D. Braccia, R. Ristuccia, A. Mori (New York, NY, USA)

    Objective: To determine the efficacy of istradefylline combined with levodopa in PD patients experiencing motor fluctuations in a pooled analysis of 4 pivotal, randomized, placebo-controlled…
  • MDS Virtual Congress 2020

    Clinical research of serum uric acid levels in Parkinson’s disease

    J.W Wu, T. Wang (Wuhan, China)

    Objective: To analyzed the variation of uric acid (UA) traits in different Hoehn-Yahr staging in Parkinson's disease (PD). Background: PD is a common neurodegenerative disease.…
  • MDS Virtual Congress 2020

    Postmenopausal hormone therapy and Alzheimer’s disease, dementia, and Parkinson’s disease: A systematic review and time-response meta-analysis

    M. wu, M. Ye (Nanjing, China)

    Objective: The study aim was to determine the relation between menopausal hormone therapy and Alzheimer's disease, dementia, and Parkinson's disease in human subjects. Background: We…
  • « Previous Page
  • 1
  • …
  • 1131
  • 1132
  • 1133
  • 1134
  • 1135
  • …
  • 1942
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley